People: Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

99.07USD
11 Jul 2014
Price Change (% chg)

$1.25 (+1.28%)
Prev Close
$97.82
Open
$98.08
Day's High
$99.74
Day's Low
$97.25
Volume
471,769
Avg. Vol
689,314
52-wk High
$99.74
52-wk Low
$58.15

Search Stocks

Mueller, Peter 

Brief Biography

Dr. Peter Mueller, Ph.D., is no longer Executive Vice President - Global Research and Development, Chief Scientific Officer of Vertex Pharmaceuticals Inc., effective October 31, 2014. Dr. Mueller is Company's Executive Vice President, Global Research and Development, a position he has held since May 2009, and has been Company's Chief Scientific Officer since July 2003. Dr. Mueller was Company's Executive Vice President, Drug Innovation and Realization, from February 2006 to May 2009, and Company's Senior Vice President, Drug Discovery and Innovation, from July 2003 to February 2006. Prior to joining the Company, Dr. Mueller was the Senior Vice President, Research and Development, of Boehringer Ingelheim Pharmaceuticals, Inc., with responsibility for the development of all drug candidates in the company's portfolio in North America. He led research programs in the areas of immunology, inflammatory cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery of numerous development candidates and held several positions in basic research, medicinal chemistry and management. Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretic Organic Chemistry. He completed fellowships in quantum pharmacology at Oxford University and in biophysics at Rochester University.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
619,846 -- 3,011,320 4,176,150

Options Compensation

  Quantity Market Value
Exercisable 115,875 1,419,840.00
Unexercisable 184,925 2,350,300.00
Exercised 167,300 8,333,100.00
Name Fiscal Year Total

Jeffrey Leiden

13,126,500

Ian Smith

4,184,760

Peter Mueller

4,176,150

Stuart Arbuckle

4,819,020

Jeffrey Chodakewitz

--

Kenneth Horton

4,539,550
As Of 30 Dec 2013
Search Stocks